[A leukotriene antagonist (montelukast) in the treatment of atopic dermatitis in pediatric patients].

Background: Leukotrienes participate in certain biological activities such as contraction of human airway muscle, increased vascular permeability, chemotaxis and allergen-induced early and late responses.

Objective: To evaluate the leukotriene antagonist montelukast in patients with atopic dermatitis unresponsive to traditional treatment.

Methods: Eighteen children with atopic dermatitis were treated with 5 mg of chewable montelukast every 24 hs during a period of 24 weeks. Patient's history was utilized as a control for each individual. On each visit, every child was assessed by a single observer and objectively scored for disease extent and severity. In addition every parent filled a similar evaluation.

Results: There was statistical improvement (p < 0.01) when values before and after treatment were analyzed, although no improvement was reported in five. No adverse reactions were reported.

Conclusion: Findings suggest that leukotriene antagonists can be used as an adjunct treatment on patients with atopic dermatitis that are refractory to traditional management.